Characteristics Associated with Early Worsening of Retinopathy in Patients with Type 2 Diabetes Diagnosed with Retinopathy at Their First Visit: A Retrospective Observational Study

Table 3

Multivariate logistic regression analysis of possible factors for retinopathy progression in patients with simple diabetic retinopathy.

		OR	95% CI	value
Model Δ3 M-1	Δ3M HbA1c (−1%)	1.30	0.92–1.89	0.14
Model Δ3 M-2	Δ3 M HbA1c (−1%)	0.84	0.43–1.55	0.58
	Baseline HbA1c (+1%)	1.61	0.95–2.97	0.08
Model Δ3 M-3	Δ3M HbA1c (−1%)	1.15	0.78–1.72	0.48
	Therapy intensification (yes)	2.97	0.73–12.8	0.13
Model Δ3 M-4	Δ3 M HbA1c (−1%)	0.81	0.40–1.50	0.51
	Baseline HbA1c (+1%)	1.51	0.87–2.83	0.15
	Therapy intensification (yes)	2.38	0.55–10.3	0.25
Model Δ6 M-1	Δ6 M HbA1c (−1%)	1.24	0.91–1.73	0.17
Model Δ6 M-2	Δ6 M HbA1c (−1%)	0.81	0.44–1.44	0.46
	Baseline HbA1c (+1%)	1.67	0.94–3.07	0.08
Model Δ6 M-3	Δ6M HbA1c (−1%)	1.10	0.77–1.58	0.60
	Therapy intensification (yes)	3.19	0.74–14.6	0.12
Model Δ6 M-4	Δ6 M HbA1c (−1%)	0.75	0.40–1.37	0.36
	Baseline HbA1c (+1%)	1.59	0.88–2.96	0.13
	Therapy intensification (yes)	2.73	0.60–12.4	0.19
Model Δ12 M-1	Δ12 M HbA1c (−1%)	1.42	1.04–2.03	0.03^*
Model Δ12 M-2	Δ12 M HbA1c (−1%)	1.25	0.66–2.50	0.50
	Baseline HbA1c (+1%)	1.16	0.59–2.22	0.66
Model Δ12 M-3	Δ12 M HbA1c (−1%)	1.29	0.91–1.90	0.17
	Therapy intensification (yes)	2.48	0.57–11.3	0.23
Model Δ12 M-4	Δ12M HbA1c (−1%)	1.20	0.62–2.43	0.58
	Baseline HbA1c (+1%)	1.09	0.55–2.12	0.81
	Therapy intensification (yes)	2.41	0.54–10.7	0.25
Model baseline HbA1c	Baseline HbA1c (+1%)	1.38	1.02–1.92	0.04^*
Model therapy intensification	Therapy intensification (yes)	3.21	0.94–11.7	0.06
Model baseline intensification	Baseline HbA1c (+1%)	1.26	0.90–1.80	0.19
	Therapy intensification (yes)	2.59	0.62–11.2	0.19

^*.